168 related articles for article (PubMed ID: 38044665)
1. Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting.
Corbeil O; Brodeur S; Courteau J; Béchard L; Huot-Lavoie M; Angelopoulos E; Di Stefano S; Marrone E; Vanasse A; Fleury MJ; Stip E; Lesage A; Joober R; Demers MF; Roy MA
Br J Psychiatry; 2024 Mar; 224(3):98-105. PubMed ID: 38044665
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder.
Solmi M; Fornaro M; Toyoshima K; Carvalho AF; Köhler CA; Veronese N; Stubbs B; de Bartolomeis A; Correll CU
CNS Spectr; 2019 Oct; 24(5):479-495. PubMed ID: 30460884
[TBL] [Abstract][Full Text] [Related]
3. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults.
Hamard J; Rousseau V; Durrieu G; Garcia P; Yrondi A; Sommet A; Revet A; Montastruc F
BMJ Ment Health; 2024 Apr; 27(1):. PubMed ID: 38609318
[TBL] [Abstract][Full Text] [Related]
4. Adverse Gestational Outcomes Associated With Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.
Andrade C
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505179
[TBL] [Abstract][Full Text] [Related]
5. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
6. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
7. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
8. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
9. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
11. Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
Merrill RM; Thygerson SM; Palmer CA
Pharmacopsychiatry; 2016 Mar; 49(2):45-50. PubMed ID: 26829453
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Stiefel G; Besag FM
Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
[TBL] [Abstract][Full Text] [Related]
13. [Antipsychotic agents and stimulants: a judicious combination?].
de Jong MH; Eussen ML; van Gool AR
Tijdschr Psychiatr; 2010; 52(1):57-61. PubMed ID: 20054798
[TBL] [Abstract][Full Text] [Related]
14. Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.
Levy E; Traicu A; Iyer S; Malla A; Joober R
Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S48-52. PubMed ID: 25886680
[TBL] [Abstract][Full Text] [Related]
15. [ADD psychosis: treatment with antipsychotics and methylphenidate?].
Blom JD; Kooij JJ
Tijdschr Psychiatr; 2012; 54(1):89-93. PubMed ID: 22237615
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Awudu GA; Besag FM
Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
[TBL] [Abstract][Full Text] [Related]
17. Treatment of adult ADHD and comorbid disorders.
Young JL
CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
[No Abstract] [Full Text] [Related]
18. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Guertin J; LeLorier J; Durand M; Gow R; Holbrook A; Levine M
J Popul Ther Clin Pharmacol; 2014; 21(3):e357-69. PubMed ID: 25326915
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study.
Zheng Y; Fukasawa T; Yamaguchi F; Takeuchi M; Kawakami K
J Atten Disord; 2024 Feb; 28(4):439-450. PubMed ID: 38084080
[TBL] [Abstract][Full Text] [Related]
20. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study.
Hollis C; Chen Q; Chang Z; Quinn PD; Viktorin A; Lichtenstein P; D'Onofrio B; Landén M; Larsson H
Lancet Psychiatry; 2019 Aug; 6(8):651-658. PubMed ID: 31221557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
